TP53 and ovarian carcinoma: Interestingly, we have reported the ability of PAX2 to suppress the routine induction of P53 expression in MOSE cells after treatment with cisplatin and the expression of P53 in a mouse model of ovarian cancer, raising the possibility that in STIC, the loss of PAX2 may be a mechanism by which P53 expression is increased [40,58].